Cargando…

Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study

INTRODUCTION: Although four kinds of Alzheimer’s disease (AD) drugs are available at present there was only one drug until 2011 in Japan. This study aimed to elucidate prescription trends of these medications for AD in Japanese outpatients before and after the new drug releases in 2011. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadohara, Kimiko, Sato, Izumi, Doi, Yuko, Arai, Masaru, Fujii, Yosuke, Matsunaga, Toshiyuki, Kawakami, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447550/
https://www.ncbi.nlm.nih.gov/pubmed/27896785
http://dx.doi.org/10.1007/s40120-016-0057-1
_version_ 1783239365508464640
author Kadohara, Kimiko
Sato, Izumi
Doi, Yuko
Arai, Masaru
Fujii, Yosuke
Matsunaga, Toshiyuki
Kawakami, Koji
author_facet Kadohara, Kimiko
Sato, Izumi
Doi, Yuko
Arai, Masaru
Fujii, Yosuke
Matsunaga, Toshiyuki
Kawakami, Koji
author_sort Kadohara, Kimiko
collection PubMed
description INTRODUCTION: Although four kinds of Alzheimer’s disease (AD) drugs are available at present there was only one drug until 2011 in Japan. This study aimed to elucidate prescription trends of these medications for AD in Japanese outpatients before and after the new drug releases in 2011. METHODS: This descriptive study of pharmacy claims databases analyzed outpatient prescription data from community pharmacies across Japan. The study patients were 20 years or older and first administered medications for AD (donepezil, memantine, rivastigmine, or galantamine) between January 2010 and September 2014. They were grouped on the basis of the year of their initial medications for AD administration into the 2010–2011 and 2012–2014 groups (1 and 2, respectively) and their characteristics and AD treatments were summarized by group. The subanalyses used a multivariable logistic regression model to examine the relationship between patient characteristics and discontinuation or change to combination therapy within a year. RESULTS: A total of 103,592 patients (group 1 and 2, 28,581 and 75,011, respectively) were prescribed medications for AD during the study period. The group 1 and 2 mean ± standard deviation (SD) ages were 79.6 ± 7.4 and 80.9 ± 7.3 years while female patients constituted 64.0% and 64.5%, respectively. Furthermore, in groups 1 and 2 patients, 99.0% and 94.3% received a medication for AD monotherapy, 92.3% and 59.6% were prescribed donepezil, and 40.5% and 41.5% discontinued treatment within a year, respectively. The subanalyses suggest that being at least 85 years old strongly correlated with treatment discontinuation and change to combination therapy within a year. CONCLUSION: Although the prescription proportions of the various medications for AD have changed since 2011, no apparent changes occurred in the patient characteristics of those who initiated AD treatment between 2010–2011 and 2012–2014.
format Online
Article
Text
id pubmed-5447550
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-54475502017-06-13 Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study Kadohara, Kimiko Sato, Izumi Doi, Yuko Arai, Masaru Fujii, Yosuke Matsunaga, Toshiyuki Kawakami, Koji Neurol Ther Original Research INTRODUCTION: Although four kinds of Alzheimer’s disease (AD) drugs are available at present there was only one drug until 2011 in Japan. This study aimed to elucidate prescription trends of these medications for AD in Japanese outpatients before and after the new drug releases in 2011. METHODS: This descriptive study of pharmacy claims databases analyzed outpatient prescription data from community pharmacies across Japan. The study patients were 20 years or older and first administered medications for AD (donepezil, memantine, rivastigmine, or galantamine) between January 2010 and September 2014. They were grouped on the basis of the year of their initial medications for AD administration into the 2010–2011 and 2012–2014 groups (1 and 2, respectively) and their characteristics and AD treatments were summarized by group. The subanalyses used a multivariable logistic regression model to examine the relationship between patient characteristics and discontinuation or change to combination therapy within a year. RESULTS: A total of 103,592 patients (group 1 and 2, 28,581 and 75,011, respectively) were prescribed medications for AD during the study period. The group 1 and 2 mean ± standard deviation (SD) ages were 79.6 ± 7.4 and 80.9 ± 7.3 years while female patients constituted 64.0% and 64.5%, respectively. Furthermore, in groups 1 and 2 patients, 99.0% and 94.3% received a medication for AD monotherapy, 92.3% and 59.6% were prescribed donepezil, and 40.5% and 41.5% discontinued treatment within a year, respectively. The subanalyses suggest that being at least 85 years old strongly correlated with treatment discontinuation and change to combination therapy within a year. CONCLUSION: Although the prescription proportions of the various medications for AD have changed since 2011, no apparent changes occurred in the patient characteristics of those who initiated AD treatment between 2010–2011 and 2012–2014. Springer Healthcare 2016-11-28 /pmc/articles/PMC5447550/ /pubmed/27896785 http://dx.doi.org/10.1007/s40120-016-0057-1 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Kadohara, Kimiko
Sato, Izumi
Doi, Yuko
Arai, Masaru
Fujii, Yosuke
Matsunaga, Toshiyuki
Kawakami, Koji
Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
title Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
title_full Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
title_fullStr Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
title_full_unstemmed Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
title_short Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
title_sort prescription patterns of medications for alzheimer’s disease in japan from 2010 to 2015: a descriptive pharmacy claims database study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447550/
https://www.ncbi.nlm.nih.gov/pubmed/27896785
http://dx.doi.org/10.1007/s40120-016-0057-1
work_keys_str_mv AT kadoharakimiko prescriptionpatternsofmedicationsforalzheimersdiseaseinjapanfrom2010to2015adescriptivepharmacyclaimsdatabasestudy
AT satoizumi prescriptionpatternsofmedicationsforalzheimersdiseaseinjapanfrom2010to2015adescriptivepharmacyclaimsdatabasestudy
AT doiyuko prescriptionpatternsofmedicationsforalzheimersdiseaseinjapanfrom2010to2015adescriptivepharmacyclaimsdatabasestudy
AT araimasaru prescriptionpatternsofmedicationsforalzheimersdiseaseinjapanfrom2010to2015adescriptivepharmacyclaimsdatabasestudy
AT fujiiyosuke prescriptionpatternsofmedicationsforalzheimersdiseaseinjapanfrom2010to2015adescriptivepharmacyclaimsdatabasestudy
AT matsunagatoshiyuki prescriptionpatternsofmedicationsforalzheimersdiseaseinjapanfrom2010to2015adescriptivepharmacyclaimsdatabasestudy
AT kawakamikoji prescriptionpatternsofmedicationsforalzheimersdiseaseinjapanfrom2010to2015adescriptivepharmacyclaimsdatabasestudy